Brief Published (Dubai time, UTC+4) · event date: 2026-10-14
On October 14, 2026, the European Commission announced it had made legally binding the commitments proposed by Sanofi under the European Union antitrust rules.
These commitments follow preliminary concerns from the Commission regarding alleged smear campaigns conducted by Sanofi in Germany and France against Fluad, the only enhanced flu vaccine for vulnerable patients competing with Sanofi’s Efluelda vaccine.
The decision aims to ensure fair competition between flu vaccines in these key markets, thereby protecting the interests of vulnerable patients.
